PDCD1 and neoplasm: Our previous case report showed that rechallenge with different PD-1/PD-L1 inhibitors was associated with an increased risk of developing high-grade or steroid-resistant pneumonitis, indicating that rechallenge with another PD-1/PD-L1 inhibitor could simultaneously reactivate the immune response in the tumor microenvironment (42).